(54.227.97.219)
Users online: 2380    [ij] [ij] [ij] 
Email id
 

Research Journal of Pharmacy and Technology
Year : 2019, Volume : 12, Issue : 2
First page : ( 584) Last page : ( 588)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2019.00104.5

Interaction Study of Antioxidants with Progressive Myoclonus Epilepsy by Molecular Docking Techniques

Yadav Ruchi, Srivastava Prachi*

Amity Institute of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India-226028

*Corresponding Author E-mail: psrivastava@amity.edu, p.srivastava2@gmail.com

Online published on 18 April, 2019.

Abstract

Progressive Myoclonus Epilepsy (PME) is a rare epilepsy syndrome caused by number of genetic disorders. This syndrome contains myoclonic seizures and chronic seizures along with progressive neurological decline. Oxidative stress can result into mild or severe form of these diseases and remain the cause of several other diseases such as cardiovascular diseases, neurological diseases, malignancies, renal disease, diabetes, inflammatory, skin diseases, aging, respiratory diseases, liver diseases, and different type of viral infection. The evaluation of the effectiveness of various, antioxidants is being targeted due to clinical, trials of several neurodegenerative diseases. In this study we have seen the effectiveness of antioxidants against Progressive Myoclonus Epilepsy disease. Docking is done using Schrödinger software, interaction studies shows that Resveratrol is potential drug against myoclonus epilepsy. Further study shows that antioxidants can be better inhibitor of myoclonus epilepsy disease.

Top

Keywords

Lafora disease, antioxidants, Resveratrol, Schrödinger software, docking.

Top

  
║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
526,289,475 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.